What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

Fabio Turco; Andrew Armstrong; Gerhardt Attard; Tomasz M. Beer; Himisha Beltran; Anders Bjartell; Alberto Bossi; Alberto Briganti; Rob G. Bristow; Muhammad Bulbul; Orazio Caffo; Kim N. Chi; Caroline Clarke; Noel Clarke; Ian D. Davis; Johann de Bono; Ignacio Duran; Ros Eeles; Eleni Efstathiou; Jason Efstathiou; Christopher P. Evans; Stefano Fanti; Felix Y. Feng; Karim Fizazi; Mark Frydenberg; Dan George; Martin Gleave; Susan Halabi; Daniel Heinrich; Celestia Higano; Michael S. Hofman; Maha Hussain; Nicholas James; Rob Jones; Ravindran Kanesvaran; Raja B. Khauli; Laurence Klotz; Raya Leibowitz; Christopher Logothetis; Fernando Maluf; Robin Millman; Alicia K. Morgans; Michael J. Morris; Nicolas Mottet; Hind Mrabti; Declan G. Murphy; Vedang Murthy; William K. Oh; Ngozi Ekeke Onyeanunam; Piet Ost; Joe M. O'Sullivan; Anwar R. Padhani; Christopher Parker; Darren M.C. Poon; Colin C. Pritchard; Danny M. Rabah; Dana Rathkopf; Robert E. Reiter; Mark Rubin; Charles J. Ryan; Fred Saad; Juan Pablo Sade; Oliver Sartor; Howard I. Scher; Neal Shore; Iwona Skoneczna; Eric Small; Matthew Smith; Howard Soule; Daniel Spratt; Cora N. Sternberg; Hiroyoshi Suzuki; Christopher Sweeney; Matthew Sydes; Mary-Ellen Taplin; Derya Tilki; Bertrand Tombal; Levent Türkeri; Hiroji Uemura; Hirotsugu Uemura; Inge van Oort; Kosj Yamoah; Dingwei Ye; Almudena Zapatero; Silke Gillessen; Aurelius Omlin

doi:10.1016/j.eururo.2022.02.010

Back

What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

Journal article

Open access

Peer reviewed

What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

Fabio Turco, Andrew Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, …

European urology, Vol.82(1), pp.6-11

01/07/2022

DOI: https://doi.org/10.1016/j.eururo.2022.02.010

PMID: 35393158

Abstract

COVID-19 boost injection

COVID-19 pandemic

COVID-19 vaccine

Prostate cancer

Prostate cancer management

Telemedicine

There is a consensus in the recommendation of the coronavirus disease 2019 (COVID-19) vaccine and boost injection in prostate cancer patients. Vaccination status can influence the therapeutic choice. Telemedicine could represent a valid tool to be integrated into daily clinical practice. Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert’s treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients.

Files and links (1)

url

https://doi.org/10.1016/j.eururo.2022.02.010View

Published (Version of record) Open

Metrics

1 Record Views

See more details

Details

Title: What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021
Creators - without role: Fabio Turco - Ospedale San Luigi Gonzaga
Andrew Armstrong - Prostate Cancer Foundation
Gerhardt Attard - University College London
Tomasz M. Beer - Oregon Health & Science University
Himisha Beltran - Dana-Farber Brigham Cancer Center
Anders Bjartell - Skåne University Hospital
Alberto Bossi - Genito Urinary Oncology, Prostate Brachytherapy Unit, Goustave Roussy, Paris, France
Alberto Briganti - Vita-Salute San Raffaele University
Rob G. Bristow - University of Manchester
Muhammad Bulbul - American University of Beirut Medical Center
Orazio Caffo - Ospedale Santa Chiara
Kim N. Chi - University of British Columbia
Caroline Clarke - University College London
Noel Clarke - Salford Royal Hospital
Ian D. Davis - Eastern Health
Johann de Bono - Royal Marsden NHS Foundation Trust
Ignacio Duran - Instituto de Investigación Marqués de Valdecilla
Ros Eeles - Royal Marsden NHS Foundation Trust
Eleni Efstathiou - Houston Methodist
Jason Efstathiou - Massachusetts General Hospital
Christopher P. Evans - University of California, Davis
Stefano Fanti - Policlinico S. Orsola, Università di Bologna, Bologna, Italy
Felix Y. Feng - University of California, San Francisco
Karim Fizazi - University of Paris-Saclay
Mark Frydenberg - Monash University
Dan George - Duke University
Martin Gleave - University of British Columbia
Susan Halabi - Duke University
Daniel Heinrich - Innlandet Hospital Trust
Celestia Higano - University of British Columbia
Michael S. Hofman - University of Melbourne
Maha Hussain - Northwestern University
Nicholas James - The Institute of Cancer Research, London, UK
Rob Jones - University of Manchester
Ravindran Kanesvaran - National Cancer Centre Singapore
Raja B. Khauli - American University of Beirut Medical Center
Laurence Klotz - University of Toronto
Raya Leibowitz - Oncology institute, Shamir Medical Center, Zerifin, Israel
Christopher Logothetis - Department of Genitourinary Medical Oncology, MD Anderson Cancer Centre, Houston, TX, USA
Fernando Maluf - Beneficiência Portuguesa de São Paulo, São Paulo, SP, Brazil
Robin Millman - Patient Advocate, UK
Alicia K. Morgans - Dana-Farber Cancer Institute
Michael J. Morris - Memorial Sloan Kettering Cancer Center
Nicolas Mottet - University Hospital Nord St Etienne, St Etienne, France
Hind Mrabti - National Institute of Oncology, University hospital, Rabat, Morocco
Declan G. Murphy - Peter MacCallum Cancer Centre
Vedang Murthy - Tata Memorial Hospital
William K. Oh - Royal Marsden NHS Foundation Trust
Ngozi Ekeke Onyeanunam - University of Port Harcourt Teaching Hospital
Piet Ost - Department of Radiation Oncology, Iridium Netwerk, Wilrijk (Antwerp), Belgium
Joe M. O'Sullivan - Queen's University Belfast
Anwar R. Padhani - Mount Vernon Cancer Centre
Christopher Parker - Royal Marsden Hospital
Darren M.C. Poon - Chinese University of Hong Kong
Colin C. Pritchard - University of Washington
Danny M. Rabah - King Saud University
Dana Rathkopf - Memorial Sloan Kettering Cancer Center
Robert E. Reiter - University of California, Los Angeles
Mark Rubin - Bern Center for Precision Medicine, Bern, Switzerland
Charles J. Ryan - University of Minnesota
Fred Saad - Université de Montréal
Juan Pablo Sade - Instituto Alexander Fleming
Oliver Sartor - Tulane Cancer Center, New Orleans, LA, USA
Howard I. Scher - Memorial Sloan Kettering Cancer Center
Neal Shore - Carolina Urologic Research Center
Iwona Skoneczna - Grochowski Hospital
Eric Small - University of California, San Francisco
Matthew Smith - Massachusetts General Hospital
Howard Soule - Prostate Cancer Foundation
Daniel Spratt - University Hospitals Seidman Cancer Center
Cora N. Sternberg - Weill Cornell Medicine
Hiroyoshi Suzuki - Toho University
Christopher Sweeney - Dana-Farber Cancer Institute
Matthew Sydes - UCL Australia
Mary-Ellen Taplin - Dana-Farber Cancer Institute
Derya Tilki - Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
Bertrand Tombal - Cliniques Universitaires Saint-Luc
Levent Türkeri - Acıbadem University
Hiroji Uemura - Yokohama City University Medical Center
Hirotsugu Uemura - Kindai University
Inge van Oort - Radboud University Medical Center, Nijmegen, The Netherlands
Kosj Yamoah - Department of Radiation Oncology & Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, FL, USA
Dingwei Ye - Fudan University Shanghai Cancer Center
Almudena Zapatero - Hospital Universitario de La Princesa
Silke Gillessen - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Aurelius Omlin - University of Bern
Publication Details: European urology, Vol.82(1), pp.6-11
Publisher: Elsevier B.V
Identifiers: 9947603708331
Academic Unit: King Saud University
Language: English
Resource Type: Journal article